RxDoctor Payments Data

Rupa Goolsby, MD

Obstetrics & Gynecology · Birmingham, ALNPI 1104843192

Payments from drug & device makers

$3,093in general payments, 2019–2025

Across 169 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$491
  • Astellas Pharma US Inc$376
  • Pfizer$368
  • Sumitomo Pharma America, Inc.$249
  • Medtronic$198
  • Mayne Pharma Commercial LLC$194
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,98296%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,093 in reported general payments places this provider in the 70th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$27,925
Medicare patients
144
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron20$15,510
PremarinEstrogens, Conjugated19$9,131
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet66$8,118
Estradiol154$6,751
Raloxifene Hcl25$2,396
Estradiol (Once Weekly)Estradiol26$1,966
Tolterodine Tartrate ErTolterodine Tartrate14$1,952
Risedronate Sodium11$1,750
ValacyclovirValacyclovir Hcl50$1,594
Estradiol (Twice Weekly)Estradiol11$1,325
Clobetasol Propionate37$954
ProgesteroneProgesterone, Micronized18$683
Ibandronate Sodium25$566
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet15$435
Triamcinolone Acetonide16$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$376$15,51020 claims
PfizerPremarin$368$9,13119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →